<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
<!-- Standalone article URLs. Include only items published within the last 48 hours. -->
<url><loc>https://glp1tirzepatiderank.com/news/berberine-natures-ozempic-checked/</loc><news:news><news:publication><news:name>GLP-1 Tirzepatide Rank</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-08-03</news:publication_date><news:title>&ldquo;Nature&rsquo;s Ozempic&rdquo;, checked: berberine returns about 4 to 5 pounds</news:title></news:news></url>
<url><loc>https://glp1tirzepatiderank.com/news/glp1-coverage-and-price-check-2026-08/</loc><news:news><news:publication><news:name>GLP-1 Tirzepatide Rank</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-08-01</news:publication_date><news:title>August price check: the approved pill and the cheapest compounded programme are $37 apart</news:title></news:news></url>
<url><loc>https://glp1tirzepatiderank.com/news/select-trial-asymmetry/</loc><news:news><news:publication><news:name>GLP-1 Tirzepatide Rank</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-08-03</news:publication_date><news:title>The cardiovascular asymmetry, filed: SELECT is a placebo trial and SURPASS-CVOT is not</news:title></news:news></url>
<url><loc>https://glp1tirzepatiderank.com/news/step-8-liraglutide-gap/</loc><news:news><news:publication><news:name>GLP-1 Tirzepatide Rank</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-08-02</news:publication_date><news:title>Why the cheapest GLP-1 on most price lists lost by nine points in a head-to-head</news:title></news:news></url>
<url><loc>https://glp1tirzepatiderank.com/news/step-1-distribution/</loc><news:news><news:publication><news:name>GLP-1 Tirzepatide Rank</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-08-02</news:publication_date><news:title>STEP-1 filed: half the treated group reached 15%, and a seventh did not reach 5%</news:title></news:news></url>
</urlset>